Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TurboHawk Helps Drive Q4 Peripheral Vascular Sales Growth At ev3

This article was originally published in The Gray Sheet

Executive Summary

Device maker ev3's peripheral vascular sales advanced 8% to $73.7 million in the fourth quarter, driven by the new TurboHawk plaque excision system

You may also be interested in...



Medtronic Gains Peripheral Pipeline, Drug-Eluting Balloons With Invatec Buy

Medtronic's acquisition of Invatec will bolster the cardiac device giant's peripheral vascular offerings and add what could be the next big thing in interventional devices - drug-eluting balloons

Earnings In Brief

Ev3: Sales of neurovascular products grew 37% to $45.2 million in the third quarter, including $28.4 million in revenues from embolic devices, the Plymouth, Mass., company said Oct. 27. The growth was driven by Axium aneurysm occlusion coils and Onyx liquid embolic neurovascular access devices and balloons, as well as overseas sales of the Pipeline embolization device. Ev3 gained Pipeline through its acquisition of Chestnut Medical in June and expects U.S. approval of the device in 2011 (1"The Gray Sheet" June 8, 2009). Peripheral vascular sales rose 1% to $67.6 million, reflecting continued weakness in its atherectomy business. The company is hoping its recently bulked up atherectomy sales force and new TurboHawk atherectomy system will have an impact on ev3. The firm announced it was adding 27 reps to market the SilverHawk plaque excision system in April. Total sales for the quarter were $112.8 million, up 13% (not including $7 million in extra 2008 funds from a now-terminated agreement with Merck). Ev3 projects fiscal 2009 sales between $446 million and $450 million

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.

Topics

UsernamePublicRestriction

Register

MT028536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel